Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119154 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TSHRCYP1A2NPC1RAB9A | |
| SCHEMBL9815018 | 0.86 | ALDH1A1 (0.57) | ALDH1A1TSHRCYP1A2NPC1RAB9A | |
| SCHEMBL9815015 | 0.86 | ALDH1A1 (0.57) | ALDH1A1TSHRCYP1A2NPC1RAB9A | |
| SCHEMBL7804952 | 0.82 | ALDH1A1 (0.57) | ALDH1A1TSHRCYP1A2HDAC1 | |
| SCHEMBL11459683 | 0.82 | ALDH1A1 (0.52) | ALDH1A1TSHRCYP1A2NPC1RAB9A | |
| SCHEMBL11464547 | 0.82 | ALDH1A1 (0.67) | ALDH1A1TSHRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9170656 | 0.82 | ALDH1A1 (0.52) | ALDH1A1TSHRCYP1A2TRPV1EPHX2 | |
| SCHEMBL11459681 | 0.82 | ALDH1A1 (0.52) | ALDH1A1TSHRCYP1A2NPC1RAB9A | |
| SCHEMBL9166600 | 0.82 | ALDH1A1 (0.52) | ALDH1A1TSHRCYP1A2TRPV1EPHX2 | |
| SCHEMBL11464546 | 0.82 | ALDH1A1 (0.67) | ALDH1A1TSHRNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117247977-A | Method for synthesizing convaldehyde by enzyme method | 四川大学 | 2023-12-19 | — | — | CN | claimed |
| CN-1989235-B | Composition comprising a metal oxide and a metal oxide | GIVAUDAN SA | 2012-12-19 | — | — | CN | claimed |
| US-8163963-B2 | Process for continuous hydrogenation or hydrogenating amination | BASF SE (DE) | 2012-04-24 | — | — | US | claimed |
| US-20100081804-A1 | PROCESS FOR CONTINUOUS HYDROGENATION OR HYDROGENATING AMINATION | BASF SE (DE) | 2010-04-01 | — | — | US | claimed |
| EP-1940765-B1 | METHOD FOR CONTINUOUS HYDROGENATION OR HYDROGENATING AMINATION | BASF SE (DE) | 2009-05-13 | — | — | EP | claimed |
| JP-2009511620-A | — | — | 2009-03-19 | — | — | JP | claimed |
| EP-1940765-A1 | METHOD FOR CONTINUOUS HYDROGENATION OR HYDROGENATING AMINATION | BASF SE (DE) | 2008-07-09 | — | — | EP | claimed |
| CN-1989235-A | Composition comprising a metal oxide and a metal oxide | GIVAUDAN SA (CH) | 2007-06-27 | — | — | CN | claimed |
| WO-2007045641-A1 | METHOD FOR CONTINUOUS HYDROGENATION OR HYDROGENATING AMINATION | BASF SE (DE) | 2007-04-26 | — | — | WO | claimed |
| US-20040132807-A1 | Aurones as telomerase inhibitors | PHARMACIA ITALIA SPA (IT) | 2004-07-08 | — | — | US | claimed |
| EP-1381359-A1 | AURONES AS TELOMERASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-01-21 | — | — | EP | claimed |
| WO-2002083123-A1 | AURONES AS TELOMERASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2002-10-24 | — | — | WO | claimed |
| CN-117247977-A | Method for synthesizing convaldehyde by enzyme method | 四川大学 | 2023-12-19 | — | — | CN | disclosed |
| CN-117247977-A | Method for synthesizing convaldehyde by enzyme method | 四川大学 | 2023-12-19 | — | — | CN | disclosed |
| US-20230278946-A1 | ALPHA, BETA-UNSATURATED ALDEHYDE PRODUCTION METHOD | KAO CORPORATION (JP) | 2023-09-07 | — | — | US | disclosed |
| US-20230278946-A1 | ALPHA, BETA-UNSATURATED ALDEHYDE PRODUCTION METHOD | KAO CORPORATION (JP) | 2023-09-07 | — | — | US | disclosed |
| US-4273945-A | HYDROGENATION OF UNSATURATED ALDEHYDES | BASF AKTIENGESELLSCHAFT (DE) | 1981-06-16 | — | — | US | disclosed |
| US-4263459-A | 3-Methyl-aldehydes, processes for their preparation and their use as odorants | HAARMANN & REIMER GMBH (DE) | 1981-04-21 | — | — | US | disclosed |
| US-4241058-A | INSECTICIDES, MITICIDES, SYSTEMIC | HOFFMANN-LA ROCHE INC. (US) | 1980-12-23 | — | — | US | disclosed |
| EP-0005541-A2 | Substituted piperidine, morpholine or piperidone derivatives, fungicides containing these compounds, process for their preparation and their use, and the use of these compounds as fungicides | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1979-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278946-A1 | ALPHA, BETA-UNSATURATED ALDEHYDE PRODUCTION METHOD | ALDH1A1, AOX1, ALDH1B1 | ALDH1A1 1/4885TSHR 3377/4885CYP1A2 127/4885 |
| US-20040132807-A1 | Aurones as telomerase inhibitors | TERT, TERF2, TERF2IP | ALDH1A1 1344/4885TSHR 3411/4885CYP1A2 4324/4885 |
| US-20100081804-A1 | PROCESS FOR CONTINUOUS HYDROGENATION OR HYDROGENATING AMINATION | HRH4, HRH2, HRH3 | ALDH1A1 1980/4885TSHR 3908/4885CYP1A2 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.